Physician profile
Namita G Patel
NPI 1205818044
$8,480.34
in general payments reported to CMS, 2019-2025
27 companies · $2,563 in 2025
The $2,563 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $613 · 2022: $1,081 · 2023: $2,429 · 2024: $1,795 · 2025: $2,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,786.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,460.23 | 2021-2025 | |
| Axsome Therapeutics, INC. | $1,039.28 | 2022-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $846.39 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $646.42 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $570.99 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $518.75 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $475.08 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $404.14 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $381.91 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $344.83 | 2024-2025 | Fanapt |
| Alkermes, INC. | $214.18 | 2022-2025 | Aristada, Lybalvi |
| Almatica Pharma LLC | $205.36 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $198.90 | 2022-2024 | Quviviq |
| Neos Therapeutics, Lp | $185.69 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Tris Pharma INC | $176.37 | 2024-2025 | Dyanavel Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $176.27 | 2022-2025 | Azstarys |
| Noven Therapeutics, LLC | $139.68 | 2024-2025 | Xelstrym |
| Bausch Health US, LLC | $112.01 | 2021-2024 | Aplenzin, Wellbutrin |
| Gilead Sciences, INC. | $107.04 | 2023 | Descovy |
| Aytu Biopharma, INC. | $51.83 | 2021-2022 | |
| Owp Pharmaceuticals, INC. | $43.87 | 2021 | |
| Ironshore Pharmaceuticals INC. | $41.52 | 2022-2023 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $40.67 | 2022 | |
| Merck Sharp & Dohme LLC | $36.70 | 2022 | |
| Acadia Pharmaceuticals INC | $22.38 | 2025 | Nuplazid |
| Brainsway USA INC | $21.21 | 2023 | |
| Jazz Pharmaceuticals INC. | $18.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Namita Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.